학술논문
Waldeyer's Ring 비호치킨 림프종의 병합요법
이용수 2
- 영문명
- Combined Modality Therapy of Non-Hodgkin's Lymphoma of Waldeyer's Ring
- 발행기관
- 대한두경부종양학회
- 저자명
- 박인규(In Kyu Park) 윤상모(Sang Mo Yun) 박준식(Jun Sik Park) 김재철(Jae Cheol Kim)
- 간행물 정보
- 『대한두경부종양학회지』제15권 제1호, 22~28쪽, 전체 7쪽
- 주제분류
- 의약학 > 종양학
- 파일형태
- 발행일자
- 1999.05.30
4,000원
구매일시로부터 72시간 이내에 다운로드 가능합니다.
이 학술논문 정보는 (주)교보문고와 각 발행기관 사이에 저작물 이용 계약이 체결된 것으로, 교보문고를 통해 제공되고 있습니다.
국문 초록
영문 초록
Purpose: We performed this study retrospectively to evaluate local control, survival, prognostic factors, and failure patterns in patients with non-Hodgkin's lymphoma of Waldeyer's ring.
Materials and Methods: From April 1984 to November 1996,41 patients with non-Hodgkin's lymphoma of Waldeyer's ring were treated with combined chemotherapy and radiation therapy. Age was ranged from 19 to 73 years old with a median age of 55 years, and there were 26 male and 15 female patients. Primary site was tonsil in 26 and base of the tongue in 7 and nasopharynx in 8, and stage distribution showed stage I in 12 and stage II in 29 patients. Pathologic classification was done according to Working Formulation. There were 1 with follicular mixed small cleaved and large cell, 8 with diffuse small cleaved cell, 7 with diffuse mixed small and large cell, and 25 cases with diffuse large cell. All patients were treated with combination of chemotherapy and radiation therapy. Chemotherapy regimen consisted of either CHOP-Bleo(cyclophosphamide, adriamycin, vincristine, prednisolone, bleomycin) or COP-BLAM III(cyclophosphamide, vincristine, prednisolone, bleomycin, adriamycin, procarbazine). Radiation dose ranged from 3600cGy to 6620cGy with a median dose of 5040cGy. Follow-up time was ranged from 15 months to 159 months(median 55 months).
Results: The complete response was achieved in 98%(40/41) and partial response in 2%(1/41). The complete response rate were the followings: 66.7% for stage I and 51.7% for stage II after chemotherapy, 100% for stage I and 96.6% for stage II after overall treatment respectively. The overall survival rate and disease-tree survival rates at 5 years were 82.6% and 79.5%, respectively. Prognostic factors for overall survival were age(p=0.007), stage(p=0.03), nodal status(p=0.006) and radiation dose(p=0.003). The factors associated with disease-tree survival were stage(p=0.04), nodal status(p=0.004) and radiation dose(p=0.009). The failure patterns were analized in evaluable 35 patients with complete response. Locoregional failure was noted in 2 patients and distant metastasis in 5 patients.
Conclusion: Our results suggest that combined modality therapy is the appropriate treatment for stage I-II intermediate grade non-hodgkin's lymphoma of the Waldeyer's ring. However, our material is small and the analysis is retrospective. Randomized prospective studies for combined therapy, radiation therapy alone and chemotherapy alone are needed.
목차
Abstract
서론
대상 및 방법
결과
고안 및 결론
References
해당간행물 수록 논문
- 갑상선 결절의 Ki67과 p27 발현도에 대한 분석
- 두경부종양 환자에서 경부림프절 전이의 분포에 관한 고찰
- 갑상선수술후의 저칼슘혈증
- 거대한 단발성 측경부 종물로 나타난 전이성 갑상선암 1례
- 외과적 치료를 시행한 갑상선 결절의 임상적 고찰
- 유두상 갑상선암의 수술후 재발예측인자로서 혈청 Thyroid Peroxidase의 의의
- 그레이브스병의 갑상선 절제술후 합병증
- 두경부 골수외 형질세포종의 임상적 고찰
- 편도암의 수술적용 형태에 따른 치료효과
- Waldeyer's Ring 비호치킨 림프종의 병합요법
- 두개내에서 발생하여 두개외로 연장된 설하신경초종 1례
- 갑상선 선종을 동반한 원발성 부갑상선 기능 항진증 1예
- 상악동 편평세포암종의 수술적 치료에 있어서 측두아래오목과 날개구개오목 절제의 의의
- 후두 및 하인두 편평세포암종의 경부 잠재전이율
- 갑상선 암의 판정에 대한 술전 초음파의 의의
- 급성 췌장염으로 발현된 일차성 부갑상선 기능항진증 1예
참고문헌
관련논문
의약학 > 종양학분야 BEST
- 방사선 치료에 내성이 유도된 두경부 편평세포암에 대한 종양살상 헤르페스 바이러스의 유전자 치료 효과
- 식도암에서 근치적 절제술 후 방사선치료의 역할
- 두경부암에서 면역회피 기전과 면역항암제 치료
의약학 > 종양학분야 NEW
- Radiomics in stereotactic body radiotherapy for non-small cell lung cancer: a systematic review and radiomic quality score study
- Evidence-based clinical recommendations for hypofractionated radiotherapy: exploring efficacy and safety - Part 1. Brain and head and neck
- Hypofractionated radiation therapy for head and neck cancers in the era of intensity-modulated radiation therapy
최근 이용한 논문
교보eBook 첫 방문을 환영 합니다!
신규가입 혜택 지급이 완료 되었습니다.
바로 사용 가능한 교보e캐시 1,000원 (유효기간 7일)
지금 바로 교보eBook의 다양한 콘텐츠를 이용해 보세요!